Rockefeller Capital Management’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
Other funds holding AKBA
Rockefeller Capital Management's AKBA Position: Q3 2026 in Review
Rockefeller Capital Management sold out of Akebia Therapeutics (AKBA) in Q3 2026, closing a stake of 1,871 shares — an estimated $2.13K sold.
Rockefeller Capital Management first reported a position in AKBA in Q1 2020 and held it in 14 quarters. The position peaked at $7K in Q2 2021. 156 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.
- Rockefeller Capital Management reported no remaining Akebia Therapeutics position as of Q3 2026 after selling out during the quarter.
- Rockefeller Capital Management sold 1,871 Akebia Therapeutics shares in Q3 2026, an estimated $2.13K.
- Rockefeller Capital Management first reported a position in Akebia Therapeutics in Q1 2020 and held it in 14 quarters.
- Rockefeller Capital Management's Akebia Therapeutics position peaked at $7K in Q2 2021.
- 156 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.